PMID- 26401086
OWN - NLM
STAT- MEDLINE
DCOM- 20161011
LR  - 20181113
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 21
IP  - 35
DP  - 2015 Sep 21
TI  - Effect of tumor necrosis factor-alpha antagonists on oxidative stress in patients 
      with Crohn's disease.
PG  - 10208-14
LID - 10.3748/wjg.v21.i35.10208 [doi]
AB  - AIM: To investigate changes in oxidative stress in Crohn's disease (CD) before 
      and after anti-tumor necrosis factor (TNF)-alpha treatment. METHODS: A total of 42 
      patients with active CD, who were scheduled to be treated by anti-TNF-alpha 
      antibodies, were enrolled. Serum levels of diacron-reactive oxygen metabolites 
      (d-ROM), biological antioxidant potential (BAP), and modified ratio of oxidative 
      stress and antioxidant capacity (m-OA) were measured using the Free Radical 
      Analytical System before and 8 wk after induction of therapy with infliximab or 
      adalimumab. The values for oxidative stress were correlated with disease activity 
      and clinical response as determined by the CD activity index (CDAI) at 8 and 54 
      wk after the therapy. RESULTS: Prior to treatment, d-ROM showed significant 
      correlations with CDAI (r = 0.42, P < 0.01). There was a significant negative 
      correlation between m-OA and CDAI before and after treatment (r = -0.48 vs r = 
      -0.42, P < 0.01). CDAI and d-ROM had decreased significantly by 8 wk after 
      treatment (CDAI; 223.3 +/- 113.2 vs 158.3 +/- 73.4, P < 0.01, d-ROM; 373 +/- 133 vs 312 
      +/- 101, P < 0.05). However, neither BAP nor m-OA had changed significantly. In 
      patients who had responded to the treatment at 8 wk, d-ROM, BAP, and m-OA levels 
      before treatment did not differ significantly between patients with and without 
      loss of response. CONCLUSION: Anti-TNF-alpha therapy decreases oxidative stress in 
      patients with CD, but does not alter the production of antioxidants. 
      Dysregulation of antioxidants may be associated with the disease.
FAU - Yamamoto, Kazunari
AU  - Yamamoto K
AD  - Kazunari Yamamoto, Toshimi Chiba, Takayuki Matsumoto, Division of 
      Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate 
      Medical University, Morioka City, Iwate 020-8505, Japan.
FAU - Chiba, Toshimi
AU  - Chiba T
AD  - Kazunari Yamamoto, Toshimi Chiba, Takayuki Matsumoto, Division of 
      Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate 
      Medical University, Morioka City, Iwate 020-8505, Japan.
FAU - Matsumoto, Takayuki
AU  - Matsumoto T
AD  - Kazunari Yamamoto, Toshimi Chiba, Takayuki Matsumoto, Division of 
      Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate 
      Medical University, Morioka City, Iwate 020-8505, Japan.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Crohn Disease/blood/diagnosis/*drug therapy/immunology
MH  - Female
MH  - Gastrointestinal Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Infliximab/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Pilot Projects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
MH  - Young Adult
PMC - PMC4572802
OTO - NOTNLM
OT  - Anti-tumor necrosis factor-alpha antibody
OT  - Crohn's disease
OT  - Oxidative stress
OT  - Severity
EDAT- 2015/09/25 06:00
MHDA- 2016/10/12 06:00
PMCR- 2015/09/21
CRDT- 2015/09/25 06:00
PHST- 2015/03/25 00:00 [received]
PHST- 2015/06/01 00:00 [revised]
PHST- 2015/07/15 00:00 [accepted]
PHST- 2015/09/25 06:00 [entrez]
PHST- 2015/09/25 06:00 [pubmed]
PHST- 2016/10/12 06:00 [medline]
PHST- 2015/09/21 00:00 [pmc-release]
AID - 10.3748/wjg.v21.i35.10208 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2015 Sep 21;21(35):10208-14. doi: 
      10.3748/wjg.v21.i35.10208.